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Abstract Multidisciplinary, evidence-based European
Guidelinesforqualityassuranceincolorectalcancerscreening
and diagnosis have recently been developed by experts in a
pan-European project coordinated by the International Agen-
cy for Research on Cancer. The full guideline document
includes a chapter on pathology with pan-European recom-
mendations which take into account the diversity and
heterogeneity of health care systems across the EU. The
present paper is based on the annex to the pathology chapter
which attempts to describe in greater depth some of the issues
raised in the chapter in greater depth, particularly details of
special interesttopathologists.Itispresentedheretomakethe
relevant discussion known to a wider scientific audience.
Keywords Colorectal cancer screening.Multidisciplinary
evidence-based guidelines.Quality assurance.
Histopathology.Classification.Precursor lesions
Introduction
In 2004 and 2006 the European Union (EU) was expanded to
include 12 new Member States. This has added greater
diversity and heterogeneity in health care systems, including
professional and technical standards and capacities. The
authors and editors of the European guidelines for quality
assurance in colorectal cancer screening and diagnosis have
been conscious of the importance of raising and maintaining
standards across the EU. While recommending standards and
procedures that are of prime importance for mortality reduc-
tion, an equitable balance of best practice and ease of service
deliverythatcanbeachievedacrossawidespectrumofcultural
and economic healthcare settings has been sought. Care was
taken to avoid promotion of recent research findings before
theirputativebenefithasbeendemonstratedinclinical practice.
In preparing the guidelines chapter with pan-European
recommendationsdealingwithpathology[1], the authors were
aware that the rapid pace of developments in the field and the
diversity in the EU would not permit a discussion of some of
the issues in greater depth, even though a more detailed
discussion would be welcomed by a number of readers,
particularly regarding items of special interest to pathologists.
All of the guideline recommendations for quality assurance in
pathology are therefore presented in the preceding paper and
in the pathology chapter in the full guidelines document [1],
on which the preceding paper is based.
The present paper is based on the annex to the chapter
on pathology in the full guidelines document [2]. It
attempts to address the limitations of the discussion in the
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statements in the following text should be understood as
guideline recommendations. The authors and editors also
felt that an annex would be the appropriate place to point
out new insights not yet widely adopted in Europe that may
be relevant to future updates of the guidelines.
Grading of neoplasia
In the present European Guidelines [1], a classification
system for colorectal neoplasia has been recommended based
on a modified version of the revised Vienna classification
(see Grading of Neoplasia in main publication). For readers
not yet familiar with the Vienna classification, it may be
helpful to note that it is the first classification to include a
clinical recommendation for each neoplastic category.
Furthermore, the system was developed to improve diagnos-
tic reproducibility in the interpretation of biopsy specimens
and subsequent resection specimens [3–5]. Strictly speaking,
the Vienna classification is only valid for biopsy specimens,
since a clinical recommendation should follow. However, to
avoid diagnostic inconsistencies, the Vienna classification
can be used for resection specimens as well.
In the Vienna classification and hence in the European
Guidelines, the term neoplasia rather than dysplasia is used
to refer to epithelial tumours associated with and without
chronic inflammatory diseases. Whereas the Vienna classi-
fication differentiates between strictly intraepithelial lesions
and those involving the lamina propria, the European
Guidelines only refer to mucosal neoplasia that may or
may not involve the lamina propria (see Grading of
Neoplasia in main publication). More importantly, the EU
Guidelines recommend a two-tiered grading of mucosal
neoplasia. The pathologist must decide whether a neoplastic
mucosal lesion can be categorised as low or as high grade;
for criteria see Table 1.
As always in neoplasia, the lesion should reach the
mucosal surface (no epithelial maturation). Undermining
edges of an adjacent carcinoma should be excluded.
The criteria in Table 1 can be weighted. The most
important criteria for the diagnosis of carcinoma are the
lateral expansion and the number of nuclear rows. In
carcinoma, the number of nuclear rows should change
within a single gland. High-grade neoplasia is diagnosed
when the nuclear rows do not exceed two to five nuclei,
and the glands do not show lateral expansion. Low-grade
neoplasia is diagnosed when the nuclear rows do not
exceed two to three nuclei [6–8].
In histopathology, the entity of carcinoma in situ is
generally defined as carcinoma confined to the epithelial
layer. In squamous epithelium such an entity can be readily
diagnosed. In columnar epithelium, an analogous entity
should theoretically also exist. However, to date there are no
exact criteria that would permit diagnosis and that would
enable the histopathologist to distinguish high-grade intra-
epithelial neoplasia from carcinoma limited to the epithelial
layer that is not invasive in the lamina propria. Therefore,
throughoutthegastrointestinaltract,useofthetermcarcinoma
in situ is not recommended for respective lesions in columnar
epithelium. The term intramucosal carcinoma is widely
introduced in the upper GI tract but not yet in the lower GI
tract (see also below: Definition of invasion). We prefer the
term “mucosal neoplasia” to intraepithelial neoplasia as high-
grade dysplasia can contain epithelial neoplasia and invasion
into the lamina propria according to the TNM classification.
Classification of serrated lesions
Terminology
The terminology is still under discussion. Serrated lesions can
be regarded as a continuous spectrum of colorectal lesions
Table 1 Grading of gastrointestinal neoplasia
Normal Low-grade mucosal/intraepithelial
neoplasia (LGMN)
High-grade mucosal/intraepithelial
neoplasia (HGMN)
Invasive cancer
Glands Non-branching Villous Branching, cribriform, irregular, solid Branching, cribriform,
irregular, solid
Expansion Up/down Till surface Till surface Lateral expansion
Epithelial differentation Up/down Top–down and exceptional down–top No maturation towards surface
Goblet cells + + + −/+ Retronuclear, atypic
Nuclear rows 1 2–32 –5 Changing
Nuclear size Small, basal Palisading Enlarged Vesicular
Chromatin Few + + + + +/+ + +
Nucleoli None None Few small Several/prominent
Source: modified from [67–69]
22 Virchows Arch (2011) 458:21–30with increasingly more pronounced serrated morphology
starting with a hyperplastic polyp (HP) and progressing to
sessile serrated lesions (SSLs, sometimes referred to as
sessile serrated adenomas or sessile serrated polyps),
traditional serrated adenomas (TSA) and leading, finally,
to adenocarcinoma. Not only the adenomatous component
but also other alterations associated with more pronounced
serrated morphology may potentially progress to cancer (see
Table 2).
The situation involving sessile serrated lesionsi sc o m p l i -
cated as these lesions only reveal complex structural
abnormalities, not adenomatous changes. Therefore, these
lesions are neither adenomatous nor are they neoplastic. This
is why Kudo et al. [9] and Lambert et al. [10] recommended
that these lesions no longer be called adenomas; instead they
should be referred to as SSLs. Few of these lesions are
reported to rapidly progress to invasive carcinoma, [11].
Those few cases that do progress rapidly, particularly in the
right colon, may be expected to appear more frequently as
interval cancers. TSAs, unlike SSLs, do contain adenoma-
tous alterations, albeit sometimes quite subtle [12]; they are
therefore termed correctly and treatment and surveillance
should correspond to that of adenomas (see Chapters 8 and 9
in the full guideline document [13, 14]).
Due to the continuous spectrum in the serrated pathway
to colorectal cancer, lesions with combinations of serrated
morphology and adenomatous cytology can be observed. If
more than one histopathologic type in the serrated spectrum
(HP, SSL, TSA) is discernible in a given lesion, or at least
one type in combination with adenomatous tissue, such
lesions are referred to as mixed polyps.
The different histopathologic types (e.g. HP and SSL,
SSL and TSA, adenoma and SSL, etc.) must be stated in
the diagnosis.
Hyperplastic polyp
Hyperplastic polyps (HPs) are composed of elongated
crypts (no complex architecture) with serrated architecture
in the upper half of the crypt. These polyps usually show
some proliferation in the basal (non-serrated) part of the
crypts (regular proliferation). Nuclei are small, regular,
basal-orientated and lacking hyperchromasia, but with
stratification of the upper (serrated) half of the crypts, and
without cytological or structural signs of neoplasia.
Differences in the appearance of the cytoplasma permit
recognition of three types:
& Microvesicular type
& Goblet-cell-rich type
& Mucin-poor type.
The microvesicular variant greatly predominates, but
distinction between types is subject to wide interobserver
variation, especially in small lesions, and is not always
possible. Currently, routine subclassification is therefore
neither feasible, nor has it been shown to be beneficial.
At the molecular level the microvesicular variant of HP
may be the precursor lesion for sessile serrated lesion, and a
goblet-cell-rich HP may be the precursor lesion for a
traditional serrated adenoma [15–17]. Routine distinction of
these types is not necessary.
Sessile serrated lesion
Sessile serrated lesions are described in the literature as
“sessile serrated adenoma” and are often found in the right
colon. This is a misnomer since sessile serrated lesions do
not contain adenomatous changes [9, 10, 18].
To date, four synonymously used terms exist for these
lesions: sessile serrated adenoma [19], superficial serrated
adenoma [20], type 1 serrated adenoma [21] and serrated
polyp with abnormal proliferation [17].
We recommend using only the term sessile serrated
lesion and avoiding use of any other terms for this entity.
This recommendation is given in full awareness that sessile
serrated lesions do not show histological signs of an
adenoma, but, like adenomas, they should be excised if
detected during an endoscopic examination. Currently, even
in the hands of expert GI pathologists, the agreement on the
sub-types of serrated lesions is only moderate [22].
The vast majority of SSLs will not progress to
adenocarcinoma. Histological criteria of these sessile,
Table 2 Continuous spectrum of serrated lesions and possible combinations of histopathologic types
Lesion Neoplasia Risk of malignant transformation
Hyperplastic polyp No Minimal
Sessile serrated lesion No Slightly increased but exact data are missing (rapid transformation may be possible in a short time)
Traditional serrated adenoma Yes Increased and suggested worse prognosis than carcinomas arising in sessile serrated lesions
Mixed polyp Yes Increased, but exact data are not available
Adenoma (tubular, villous) Yes Increased, 17 years on average
Every lesion can give rise to adenocarcinoma
Most of the adenocarcinomas are believed to derive from adenomatous components
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zone with structural distortion, usually most pronounced in
dilatation of the crypts, particularly near the base. Abundant
mucus production is usually also observed as pools of
mucin in the lumen of the crypts and on the surface of the
mucosa. SSLs are found mainly in the right colon and may
be misdiagnosed as hyperplastic polyps. Clues to the
correct diagnosis include location and large size. As
discussed above, cytological signs of “neoplasia” are
lacking, but structural abnormalities are present, i.e.
glandular branching [18].
Sessile serrated lesions have an elevated serration index
and serration in the basal half of crypts with basal dilation of
crypts. The epithelium/stroma-ratio is believed to be >50% in
SSL. There is crypt branching with horizontal growth (above
muscularis mucosae; e.g. T- and L-shaped glands) and often
pseudoinvasionintothesubmucosallayer,rectangulardilation
of whole crypts with and without presence of mucus,
increased number of goblet cells at the base of the crypts,
vesicular nuclei with prominent nucleoli and proliferation
zone in the middle of the crypts. Currently there is insufficient
evidence available in the literature for weighting of these
criteria.
A well-oriented polypectomy is mandatory for the
identification of such histological features. Correct assess-
ment of the deepest portions of the mucosa is impossible in
superficial or tangentially cut lesions [15, 16].
Further criteria include an often asymmetrical expansion
of the proliferation zone into the middle third of crypts.
Often mild cytological atypia (slightly enlarged vesicular
nuclei, nucleoli) is found without clear signs of neoplasia
(dysplasia).
BRAF mutations depend on the type and location of
lesion (see Table 3).
Other abnormalities include:
& The majority of SSL and TSA show CpG island
methylator phenotype (CIMP) and promoter methyla-
tion of hMLH1
& BRAF mutations in 8–10% of all colorectal cancer
(CRC; 27–76% of CIMP and sporadic MSI-H CRC)
& BRAF mutations in the majority of SSL and TSA (also
microvesicular variant of HP, especially proximal), but
rarely (0–5%) in adenoma [23–34].
The frequency of sessile serrated lesions in small
retrospective series is estimated at 2–11% of all mucosal
lesions in the colon [35, 36]; between 8% and 23% are
misdiagnosed as hyperplastic polyps with an interobserver
variation of up to 40% [17, 37–39].
The histological features separating HPs from SSLs
constitute a continuous spectrum, and intermingled features
can often be seen. This could explain the moderate
interobserver concordance (k=0.47) and the overlapping
proliferative activity, and may justify establishing semi-
quantitative criteria for diagnosis (e.g. >30% of undiffer-
entiated cells) [40, 41]. Only a few immunohistochemical
markers (Ki67, Ki67+CK20, MUC6) have been tested for
differentiating HPs and SSAs, and their usefulness in
colorectal screening and diagnosis remains to be validated
[42, 43]. At present, such an additional immunohistochem-
ical analysis cannot be recommended (see Table 4).
In all likelihood, lesions formerly interpreted as mixed
hyperplastic and adenomatous polyp are, in fact, SSLs
complicated by conventional neoplasia, [44]. Special care
must be taken in such cases to document the respective
histopathologic components in such mixed polyps. Some-
times the conventional neoplastic part shows features other
than in classical adenomas. The nuclei are prominent, less
palisading and smaller than in classical adenomas. It is not
clear whether this type of morphology is distinct for serrated
lesions and whether any clinical implications can be drawn.
Prospective studies with risk stratification are needed to
develop more precise methods of diagnosis and recom-
mendations for classification. Sessile serrated lesions
appear to take a long time (average 17 years) to develop
into an invasive carcinoma. In contrast, an ill-defined, small
subsample of SSLs seems to rapidly progress [11, 44].
Therefore, SSLs should be completely excised, particularly
if they are located on the right side of the colon [16, 45].
Diagnosis on a biopsy is not adequate to exclude SSL
since the most severe histologic changes might only appear
Table 3 Prevalence of serrated lesions with BRAF Mutation—a prospective study of patients undergoing colonoscopy
Lesion Number (n=414) (% of all lesions) Proximal location (% of BRAF mutations) Distal location (% of BRAF mutations)
Hyperplastic polyp 120 (29) 35 (29) 85 (71)
Sessile serrated lesion 36 (9) 27 (75) 9 (25)
Trad. serrated adenoma 3 (1) 2 (66) 1 (33)
Mixed polyp 7 (2) 4 (57) 3 (43)
Tubular adenoma 237 (57) 176 (74) 61 (26)
Villous adenoma 11 (3) 6 (55) 5 (45)
Source: modified from [54]
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hyperplastic polyp [46].
The German guidelines for colorectal cancer [47]
recommend complete removal and follow-up of SSL
similar to adenomas. An intensive surveillance protocol is
recommended for sessile serrated lesions (surveillance
colonoscopy after 3–5 years subsequent to complete
excision of non-neoplastic SSL, after 1 year after excision
of SSL HGIEN [47]).
The UK Guidelines [48–51] recommend complete
excision but classify these lesions in the same risk category
as hyperplastic polyps. The existing evidence base is not
definitive as to the level of risk, and follow-up decisions
should be made locally until more evidence is forthcoming.
Traditional serrated adenoma
Traditional serrated adenomas show neoplastic crypts with
a serrated structure [52]. Compared to hyperplastic polyps,
the most striking diagnostic feature of traditional serrated
adenomas are the complex serrated morphology and the
eosinophilic, “dysplastic” cytoplasm that still can be
identified in cases with invasive adenocarcinoma. These
lesions also frequently show BRAF mutations and CIMP
with hMLH1 promoter methylation. Additionally, so-called
intraepithelial microacini can be observed in the upper half
of the mucosa (ectopic crypt formation). Often, these
lesions are located in the distal colon and can be found
more frequently in elderly female individuals [12, 18, 43].
Mixed polyp
A mixed polyp may contain partially hyperplastic, classical
adenomatous or traditional serrated adenoma or sessile
serrated lesion components. Rather than a continuous spec-
trum such lesions most probably represent several evolution-
ary lines, depending on the order of certain abnormalities in
genes such as APC, BRAF and KRAS [15, 16]. It has to be
determined whether mixed polyps represent serrated lesions
complicated by conventional neoplasia [53].
Focal, hyperplastic-like narrowing of the basal region of
a few crypts in SSL and the findings of flat sectors or
ectopic crypt formation in SSL/TSA [43] are examples of
combinations of serrated and adenomatous components.
However, these features add no information of further
diagnostic value; they probably result from the continuous
developing nature of serrated lesions. We therefore recom-
mend that the diagnosis of mixed polyp should be restricted
to the definition given above under Terminology (i.e.
lesions with—…more than one histopathologic type in the
serrated spectrum (HP, SSL, TSA) … or at least one type in
combination with adenomatous tissue…). Mixed polyps are
serrated lesions in which more than one histopathologic
type in the serrated spectrum (HP, SSL, TSA) is discernible
in a given lesion or at least one type in combination with
classical (unserrated) adenomatous tissue. The different
histopathological types must be mentioned in the diagnosis,
e.g. mixed polyp (HP and SSL, adenoma and SSL).
Risk of progression
The vast majority of hyperplastic polyps and serrated
lesions will not undergo malignant transformation. Only a
fraction, especially in the group of sessile serrated lesions,
may progress to rapidly aggressive carcinoma [35, 54].
Hyperplastic polyps rarely progress to carcinoma. A
single case report can be found in the literature [55] and a
second (unpublished) case has been reported in southern
Germany. Interestingly, these carcinomas show features of
gastric differentiation.
Little evidence is available on which the risk of colorectal
cancer associated with serrated lesions other than hyperplastic
polyps could be reliably judged. The risk assessment for
sessile serrated lesions is not yet defined, but a subset of these
lesions appears to give rise to carcinoma often less than a few
millimeters in size. In a series of 110 traditional serrated
adenomas, 37% exhibited foci of significant neoplasia and
11% contained areas of intramucosal carcinoma [12]. Mixed
polyps (e.g., HP/TSA/SSL or HP/adenoma) seem to have at
least the same rate of progression to colorectal carcinoma as
adenomas, and the risk might be higher [56, 57].
Assessment of T1 adenocarcinoma
Careful assessment in T1 adenocarcinoma is mandatory
because a decision is required on local excision or a major
operation.
Table 4 Comparison of proliferative activity in adenoma, hyperplastic polyps, sessile serrated lesion and traditional serrated adenoma
Ki-67 Adenoma (%) Hyperplastic polyps (%) Sessile serrated lesion (%) Traditional serrated adenoma (%)
Upper 1/3 68.8 0.1 1.6 27.9
Middle 1/3 48.7 9.1 20.3 30.6
Lower 1/3 29.6 60.3 64.9 38.2
Source: modified from [38, 44]
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Firstly, accurate measurement is very important, and
measurement must be to the nearest millimeter (and not
rounded-up to the nearest 5 or 10 mm). The maximum size
of the lesion should be measured from the histological slide
and if the lesion is disrupted or too large, from the formalin-
fixed macroscopic specimen. If a biopsy is received it
should be stated that size cannot be assessed.
Tumour grade
Poorly differentiated carcinomas are identified by the
presence of either irregularly folded, distorted and often
small tubules, or the lack of any tubular formation and
showing marked cytological pleomorphism. In the absence
of good evidence, we recommend that a grade of poor
differentiation should be applied in a pT1 cancer when
ANY area of the lesion is considered to show poor
differentiation. It should be noted that this is not in
accordance with the WHO classification that recommends
a certain proportion of lesion showing poor differentiation
before diagnosing a lesion as G3. Poor differentiation
includes undifferentiated and poorly differentiated as
defined by the WHO classification [58].
Budding
Budding describes the biological behaviour of the tumour at
the front of invasion [59]. Budding or tumour cell
dissociation [60] can be divided into slight, moderate and
marked and is known from the Japanese literature of the
1950s [61] and 1990s [62].
At this time, evidence is lacking concerning reproduc-
ibility of the numerous methods for tumour budding
measurement (see Table 5). It is good practice but not
mandatory to document the presence or absence of single
tumour cells at the front of invasion and we therefore
Table 5 Measurement of tumour budding
Author Year pT Count Magnification Objective Area
(mm
2)
Classification Cut-
off
Notes
Ueno 2004 H&E ×20 0, 785 Negative/positive 5
Ueno 2002 H&E ×25 0, 385 <10/>10 10 Degree of grading agreement
Ueno 2004 H&E 250 ×25 0, 385 Low (<10)/high (>10) 10
Shinto 2005 IHC:MNF
116
×20 Low (<10)/high (>10)
moderate (10–19),
severe (>20)
Identification of cytoplasmic
fragments
Shinto 2006 3 IHC:MNF
116
×20 Low (<10)/high (>10)
moderate (10–19),
severe (>20)
Scoring of cytoplasmic
fragments called now podia
Okuyama 2002 1 and 2 H&E n.a. n.a. n.a. Present/absent 1 Endoscopically resected
tumours were excluded
Okuyama 2003 3 H&E n.a. n.a. n.a. Present/absent 1
Okuyama 2003 3 H&E n.a. n.a. n.a. Present/absent 1
Prall 2005 IHC:MNF
116
250 0, 785 Low/high 25 ROC metastatic progression;
0–120 buds range; 14
median 20,46 mean
Kazama 2006 1 IHC: CAM5.2
and AE1/AE3
n.a. n.a. n.a. Present/absent 1
Kanazawa 2007 H&E n.a. n.a. n.a. None/mild/moderate/
marked
Nakamura 2008 H&E n.a. n.a. n.a. None/mild/low moderate/
marked=high
Choi 2007 2 or
more
H&E ×20 (0–3)/(4–5)/(6–10)/(11–38)
Park 2005 2 or
more
H&E ×20 (0–3)/(4–5)/(6–9)/(10–38) Mean intesity: (+/−SD)
6,6+/−5,6
Hori 2005 H&E 200 ×40 0,05 5% of the horizontal length
of the invasive front
Yasuda 2007 H&E Present/absent
Ishikawa 2008 IHC:MNFIIb 400 Negative/positive 5
Source: modified from [65, 74–79]
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written report with an explanatory comment as budding has
been suggested as a prognostic factor in colorectal cancer
[63–65].
Site
The site of origin of each specimen should be individually
identified by the clinician and reported to the pathologist on
the histopathology request form. The pathologist should
record this on the proforma. This is important information
because the risk of lymph node metastasis from a T1
adenocarcinoma varies depending on the site and size of the
lesion (rectum vs. other locations) [66].
Definition of invasion
In columnar epithelium it is difficult to define the onset of
invasive carcinoma and reliably distinguish it from high-
grade intraepithelial neoplasia. Criteria such as single
tumour cells are more likely to be seen in more advanced
carcinomas, but not in early carcinomas. Desmoplastic
stromal reactions are also seldom seen in very early
carcinomas. However, basal membrane structures are
frequently discernible in well-differentiated early carcino-
mas [67–69], so that definitions using “invasion through the
basement membrane” are incorrect.
The WHO definition of adenocarcinoma in use when the
EU guidelines were developed excluded diagnosis of
intramucosal carcinoma in the colon or rectum, in contrast
to the accepted WHO definitions for the stomach, oesoph-
agus and small bowel. In the latter cases, a decision on
surgical versus local therapy is made based on respective
protocols. Comparable lesions in the colon and rectum are
reported as high-grade mucosal neoplasia, because a
carcinoma in the colon is defined by infiltration of the
submucosa, according to the WHO classification.
The discussion on this issue among the authors of the
pathology chapter in the EU Guidelines reflects, among
other things, concern about potential overtreatment of early
T1 carcinomas which are detected much more frequently in
a screening setting. The clinical management of a lesion
where invasion of the lamina propria has occurred is no
different from that where high-grade changes are confined
to the glands. This legitimate concern as to increased
morbidity and mortality due to miscommunication of
diagnostic criteria may be dealt with more effectively in
the future, as multidisciplinary management of lesions
detected in and outside of screening programmes advances.
The authors hope that such advances and their effective
dissemination will be stimulated by the publication of the
new EU guidelines. This, in turn, may lead to revision of
the current WHO definition of colorectal adenocarcinoma
in a future revision of the WHO classification of gastroin-
testinal tumours. Pathologists should report on what version
of the WHO and TNM classifications their diagnosis is
based.
In those cases in which intramucosal colorectal cancer is
suspected, and particularly in countries in which this
diagnosis is documented in addition to the WHO terminol-
ogy, explicit comments by the pathologist are recommen-
ded. Based on the cytological characteristics of the case, the
pathologist should indicate whether local endoscopic or
surgical removal is recommended, and the basis for this
recommendation should be indicated. This recommendation
should be discussed in a multidisciplinary conference prior
to surgery. The Japanese criteria for such stratification have
been published [55]. The updated Paris classification based
on a workshop in Feb 2008 in Kyoto [9] permits such
subclassification based on improved grouping and explains
in detail the grading criteria [10].
The use of the term carcinoma in situ introduced by the
TNM system is inadequate because the criteria are too
vague and cannot be used for columnar epithelium.
A subclassification of all carcinomas into low-risk and
high-risk based on risk of lymph node involvement should
always be undertaken. For exact criteria please see main
text of the present publication and Chapter 7 of the full
GL document [1] and the updated Paris classification
[9, 10].
Perineural invasion
Perineural invasion (PNI) was recently described as an
independent risk factor for colorectal cancer [66, 70]. PNI
is significantly associated with high tumour stage, grade
and metastases. Furthermore, PNI serves as an independent
predictor of disease-free and cancer survival [66, 70].
Recently, an association with other criteria indicating an
aggressive course of disease such as lymphatic vessel
permeation, venous invasion, tumour growth pattern,
budding [71] were described by Poeschl et al. [66]. Also,
it was described that PNI-positive tumours are more likely
to be incompletely resected, and more likely to progress
after Mayo regimen chemotherapy than PNI-negative
tumours. Lately, Poeschl et al. were able to show that
PNI is an additional independent factor for local tumour
relapse.
It is recommended to record PNI in routine sections of
colorectal cancer. According to recent studies [66, 70, 72,
73], immunohistochemistry or special stains are not
necessary to detect PNI. Prospective studies are needed to
show the clinical relevance of PNI, its relationship to other
features such as lymphatic and vascular invasion and the
benefit of alternative treatment for such more aggressive
tumours that are PNI positive.
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The rapid pace of developments in screening, diagnosis
and treatment of colorectal cancer is likely to continue
unabated in the coming years. Pathologists interested in
colorectal cancer should be aware of the topics likely to
be of future relevance to quality assurance. This may
help to recognise opportunities to continuously improve
the quality and performance of current screening and
diagnostic activities.
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